Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Seminars in Hematology|April 3, 2008
Monoclonal antibodies for the treatment of hematologic malignancies: schedule and maintenance therapyAlden Moccia, Michele Ghielmini
Expert Review of Anticancer Therapy|September 29, 2015
Chemotherapy and treatment algorithms for follicular lymphoma: a look at all optionsSara Steffanoni, Michele Ghielmini, Alden Moccia
Oncology|September 14, 2022
Decision-Making among Experts in Advanced Hodgkin LymphomaFelicitas Hitz, Noémie Lang, Ulrich Mey, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 9, 2018
Metabolic Tumour Volume for Response Prediction in Advanced-Stage Hodgkin LymphomaJasmin Mettler, Horst Müller, Conrad-Amadeus Voltin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2017
Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 TrialsPaul J Bröckelmann, Helen Goergen, Charlotte Kohnhorst, et al.
International Journal of Environmental Research and Public Health|March 19, 2020
Resources-Stratified Guidelines for Classical Hodgkin LymphomaAllan Relecom, Massimo Federico, Joseph M Connors, et al.
Blood|May 31, 2023
Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studiesDennis A Eichenauer, Ina Bühnen, Christian Baues, et al.
The Lancet. Oncology|July 13, 2025
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trialJustin Ferdinandus, Gundolf Schneider, Alden Moccia, et al.
The Lancet. Haematology|May 28, 2021
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trialStefanie Kreissl, Helen Goergen, Ina Buehnen, et al.
The Lancet. Oncology|February 4, 2021
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trialPeter Borchmann, Annette Plütschow, Carsten Kobe, et al.
Pageof 2